TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2480798

Group type: EXPERIMENTAL
Intervention: HPA-23 treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 1103207

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.035 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31335730

Group type: EXPERIMENTAL
Intervention: Microhardness testing in the anterior region of tibial diaphysis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Microhardness testing in the medial region of tibial diaphysis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Microhardness testing in the posterior region of tibial diaphysis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Microhardness testing in the lateral region of tibial diaphysis
Number of subjects: 3
Study: 28789789

Group type: EXPERIMENTAL
Intervention: Fatigue and depression
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Fatigue, sleep and pain beliefs/attitudes
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 367
Study: 26142914

Group type: EXPERIMENTAL
Intervention: Lower limb lymphedema (LLL) group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (without LLL)
Number of subjects: 53
Study: 23291729

Group type: EXPERIMENTAL
Intervention: Double dose influenza vaccine (30 μg/strain)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard dose influenza vaccine (15 μg/strain)
Number of subjects: 28
Study: 21885537

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage in addition to guidelines and exercise therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (guidelines and exercise therapy without manual lymph drainage)
Number of subjects: 160
Study: 16675716

Group type: EXPERIMENTAL
Intervention: 1 g/m² of IV methotrexate over 24 hr (Group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2 g/m² of IV methotrexate over 4 hr (Group 2)
Number of subjects: 32
Study: 15723939

Group type: EXPERIMENTAL
Intervention: Intravenous administration of m‐THPC 6 days before direct endoscopic PDT with 80 to 100 J of light for adults and 60 to 80 J for children
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study: 12477995

Group type: EXPERIMENTAL
Intervention: MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 36

Group type: COMPARATOR
Intervention: MVAC + GM‐CSF (molgramostim)
Number of subjects: 36
Study: 9605777

Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study: 7701450

Group type: EXPERIMENTAL
Intervention: Salbutamol 2 mg (S2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg (S4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol 8 mg (S8)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg (PR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study: 2634111

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study: 333188

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 300 mg every 6 hours for up to 5 days or until 1 day after chest tube removal
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31840263

Group type: EXPERIMENTAL
Intervention: Family-focused treatment for childhood depression (FFT-CD)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Individual supportive psychotherapy (IP)
Number of subjects: 134
Study: 31274720

Group type: EXPERIMENTAL
Intervention: Cementless TKA
Number of subjects: 141

Group type: COMPARATOR
Intervention: Cemented TKA
Number of subjects: 141
Study: 28711547

Group type: EXPERIMENTAL
Intervention: Adjudicated RR reports for renal scarring
Number of subjects: 607

Group type: COMPARATOR
Intervention: ALR reports for renal scarring
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Adjudicated RR reports for acute pyelonephritis
Number of subjects: 607

Group type: COMPARATOR
Intervention: ALR reports for acute pyelonephritis
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Overall agreement rate for DMSA scan reports
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Agreement on renal scarring presence
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Two of three agreement on renal scarring
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Agreement on pyelonephritis presence
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Two of three agreement on pyelonephritis
Number of subjects: 607
Study: 24690589

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (malt-dextrin)
Number of subjects: 17
Study: 24083730

Group type: EXPERIMENTAL
Intervention: CHW HBV education intervention
Number of subjects: 87
Study: 21457064

Group type: EXPERIMENTAL
Intervention: Chemical moist heat wrap
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ThermaCare heat wraps
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hydrocollator heat wraps
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moist heat
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Younger group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diabetes group
Number of subjects: 120
Study: 18021751

Group type: EXPERIMENTAL
Intervention: Haptic information presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual information presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct error feedback (haptic or visual)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall perception of haptic parallelity
Number of subjects: 0
Study: 16808682

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 40
Study: 15346754

Group type: EXPERIMENTAL
Intervention: Repair of sinus membrane perforation with freeze-dried human lamellar bone sheet (Lambone)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No repair of sinus membrane perforation (control group)
Number of subjects: 63
Study: 15046713

Group type: EXPERIMENTAL
Intervention: Novel agents tested with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of previously studied chemotherapeutic agents
Number of subjects: 0
Study: 9661327

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (nurse-led, 8-week program)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 222
Study: 7661266

Group type: EXPERIMENTAL
Intervention: 4 mg morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 0
Study: 2526101

Group type: EXPERIMENTAL
Intervention: Etodolac (600 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diclofenac (150 mg daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subjective drug preference
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 16
Study: 334083

Group type: EXPERIMENTAL
Intervention: Systemic cloxacillin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31390835

Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Reference Intakes (RIs)
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Warning symbols
Number of subjects: 1032

Group type: COMPARATOR
Intervention: No label
Number of subjects: 1032
Study: 28244897

Group type: EXPERIMENTAL
Intervention: Resting
Number of subjects: 138

Group type: COMPARATOR
Intervention: Antihypertensive medication (telmisartan)
Number of subjects: 138
Study: 26870806

Group type: EXPERIMENTAL
Intervention: Prognostic model containing 8 genes plus MSKCC clinical risk factors
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Prognostic model containing 8 genes without MSKCC risk factors
Number of subjects: 324

Group type: COMPARATOR
Intervention: Clinical risk factors alone
Number of subjects: 324
Study: 23721363

Group type: EXPERIMENTAL
Intervention: Triple therapy with amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (25 mg)
Number of subjects: 2271

Group type: COMPARATOR
Intervention: Dual therapy with valsartan (320 mg) and hydrochlorothiazide (25 mg)
Number of subjects: 2271

Group type: COMPARATOR
Intervention: Dual therapy with amlodipine (10 mg) and valsartan (320 mg)
Number of subjects: 2271

Group type: COMPARATOR
Intervention: Dual therapy with amlodipine (10 mg) and hydrochlorothiazide (25 mg)
Number of subjects: 2271
Study: 21823286

Group type: EXPERIMENTAL
Intervention: Warming‐promotion acupuncture (Group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine acupuncture (Group B)
Number of subjects: 64
Study: 19786244

Group type: EXPERIMENTAL
Intervention: Surgical thrombectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endovascular intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment of autogenous arteriovenous fistulae
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endovascular intervention for autogenous arteriovenous fistulae
Number of subjects: 0
Study: 15274674

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 11583718

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg daily) for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 9181656

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 843

Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 843
Study: 8215814

Group type: EXPERIMENTAL
Intervention: Imipramine (mean maximum daily dose, 143 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Trazodone (255 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Diazepam (26 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Antidepressants (Imipramine and Trazodone)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 230
Study: 3651278

Group type: EXPERIMENTAL
Intervention: Alcohol 0.2 g kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol 0.4 g kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g kg‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31800679

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined parecoxib and dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 29069370

Group type: EXPERIMENTAL
Intervention: idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w
Number of subjects: 1284

Group type: COMPARATOR
Intervention: Standard epirubicin/cyclophosphamide followed by paclitaxel (EC→P) q3w
Number of subjects: 1284
Study: 27364568

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) given alongside measles-rubella and yellow fever vaccines
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Fractional intradermal doses of IPV
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Measles-rubella and yellow fever vaccines co-administered with IPV
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Measles vaccine
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Poliovirus vaccine
Number of subjects: 1504
Study: 24203058

Group type: EXPERIMENTAL
Intervention: Obese men
Number of subjects: 20
Study: 22250189

Group type: EXPERIMENTAL
Intervention: Topical carmustine following intravenous O6-benzylguanine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Topical carmustine
Number of subjects: 21
Study: 19291787

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Both treatment groups (Interferon and Control)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Patients with a decrease in steatosis
Number of subjects: 1050
Study: 17574311

Group type: EXPERIMENTAL
Intervention: Lyophilized formulation of RTS,S/AS02A
Number of subjects: 34

Group type: COMPARATOR
Intervention: Liquid formulation of RTS,S/AS02A
Number of subjects: 34
Study: 15614114

Group type: COMPARATOR
Intervention: Benzathine penicillin (2.4 MU intramuscularly)
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g orally)
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Dual treatment (azithromycin and benzathine penicillin)
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Initial titers < or =1:2 (all treatments)
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Initial titers > or =1:4
Number of subjects: 952
Study: 12527500

Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulin (Pentaglobin(R)) preparation (1,300 ml immunoglobulin, equivalent to 65 g protein)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine antibiotic prophylaxis plus placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulin (Pentaglobin(R)) preparation
Number of subjects: 41
Study: 9703374

Group type: EXPERIMENTAL
Intervention: 250 microg potassium iodide daily for 4 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no iodine treatment)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Iodine-treated group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 7808903

Group type: EXPERIMENTAL
Intervention: Mental rehearsal combined with observational and physical techniques
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mental rehearsal
Number of subjects: 40
Study: 2506603

Group type: EXPERIMENTAL
Intervention: 20 mg adinazolam mesylate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40 mg adinazolam mesylate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 60 mg adinazolam mesylate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1090967

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nurses' guesses
Number of subjects: 57

Group type: COMPARATOR
Intervention: Patients' relatives' guesses
Number of subjects: 57
Study: 31123181

Group type: EXPERIMENTAL
Intervention: Hyperfiltration (iGFR levels ≥140 ml/min per 1.73 m2)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Baseline GFR <140 ml/min per 1.73 m2
Number of subjects: 446
Study: 27539079

Group type: EXPERIMENTAL
Intervention: TIPP (PolySoft mesh)
Number of subjects: 238

Group type: COMPARATOR
Intervention: ProGrip (self-fixing semi-resorbable mesh)
Number of subjects: 238
Study: 25504002

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexmedetomidine (10 µg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus clonidine (75 µg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bupivacaine plus fentanyl (15.0 µg)
Number of subjects: 84
Study: 23831069

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration (20 mL of 0.25%)
Number of subjects: 121

Group type: COMPARATOR
Intervention: No bupivacaine infiltration (control group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tubeless PCNL
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard PCNL
Number of subjects: 121
Study: 22842775

Group type: EXPERIMENTAL
Intervention: Automated assistance (AA, n = 36)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Automated assistance + calls (AAC, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Observation-only group (OO, n = 14)
Number of subjects: 100
Study: 19200277

Group type: EXPERIMENTAL
Intervention: Stanol containing food products for three months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study: 18089864

Group type: EXPERIMENTAL
Intervention: Psychoeducation (six weekly 2-hour sessions)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 262
Study: 15323591

Group type: EXPERIMENTAL
Intervention: Gepirone ER (20 mg to 80 mg daily)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Gepirone ER
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 16208074

Group type: EXPERIMENTAL
Intervention: Problem solving nursing counseling and walking exercise (12 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (same treatment as before)
Number of subjects: 59
Study: 10702886

Group type: EXPERIMENTAL
Intervention: Quinidine sulfate 200 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cilostazol 100 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cilostazol and its metabolites (OPC‐13015 and OPC‐13213)
Number of subjects: 22
Study: 8734724

Group type: EXPERIMENTAL
Intervention: Resistance load of 5 cm H2O/L/sec
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fixed flow and breathing rates
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Normal breathing, fixed flow rate, fixed breathing rate, and fixed flow and breathing rate
Number of subjects: 15
Study: 2009147

Group type: EXPERIMENTAL
Intervention: Delapril
Number of subjects: 1008
Study: 6218350

Group type: EXPERIMENTAL
Intervention: Erythromycin lauryl sulfate (A-137) alcoholic solution, applied topically 3 times daily for 8 weeks.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle (control group), applied topically 3 times daily for 8 weeks.
Number of subjects: 36
Study: 31647093

Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies using data from related individuals (sibling pairs or parent-offspring trios)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mendelian randomization studies using data from unrelated individuals
Number of subjects: 0
Study: 29027667

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 20

Group type: COMPARATOR
Intervention: CD4+ CD57+ PD-1- T cells
Number of subjects: 20
Study: 26403160

Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) plus peginterferon alfa-2b and ribavirin for 12 weeks then peginterferon alfa-2b and ribavirin for 12 weeks
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg twice daily) plus peginterferon alfa-2b and ribavirin for 24 weeks
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control: peginterferon alfa-2b and ribavirin alone for 48 weeks
Number of subjects: 294
Study: 23845385

Group type: EXPERIMENTAL
Intervention: LiTMUS trial participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous bipolar disorder efficacy studies
Number of subjects: 0
Study: 22516981

Group type: EXPERIMENTAL
Intervention: Individualized or fixed‐dose GH treatment
Number of subjects: 99
Study: 20099955

Group type: EXPERIMENTAL
Intervention: Expressive writing about the most stressful or traumatic gay-related event for 20 min a day for 3 consecutive days
Number of subjects: 77

Group type: COMPARATOR
Intervention: Expressive writing about a neutral topic for 20 min a day for 3 consecutive days
Number of subjects: 77
Study: 18474155

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 30
Study: 15631558

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study: 12491045

Group type: EXPERIMENTAL
Intervention: Aggressive polychemotherapy given both pre- and post-surgery for Ewing tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive polychemotherapy given both pre- and post-surgery for osteosarcoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy for chondrosarcomas
Number of subjects: 0
Study: 10636472

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: 10 mg flumazenil
Number of subjects: 6
Study: 9345400

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b, 8 MIU given subcutaneously every other day for 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31107394

Group type: EXPERIMENTAL
Intervention: Simulation participation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: VR observation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Television observation
Number of subjects: 8
Study: 31073124

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 µg/vilanterol 25 µg (FF/VI)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 400
Study: 28441699

Group type: EXPERIMENTAL
Intervention: Enalapril + Folic Acid (10 mg enalapril and 0.8 mg folic acid)
Number of subjects: 20702

Group type: COMPARATOR
Intervention: Enalapril alone (10 mg enalapril)
Number of subjects: 20702
Study: 26520926

Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen (darunavir 800 mg once per day + ritonavir 100 mg once per day + raltegravir 400 mg twice per day)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard regimen (darunavir 800 mg once per day + ritonavir 100 mg once per day + tenofovir 245 mg once per day + emtricitabine 200 mg once per day)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen and Standard regimen
Number of subjects: 146
Study: 23885523

Group type: EXPERIMENTAL
Intervention: Telemedicine diagnosis
Number of subjects: 414